Cove Fund congratulates Evasyst, Inc. and Lynx Biosciences, Inc. on their selection by San Diego Venture Group (SDVG) and Tech Coast Angels (TCA) as Top 10 Finalists in their jointly sponsored upcoming Quick Pitch competition, to be held on the evening of October 24 at Irwin Jacobs Hall on the Qualcomm business campus in La Jolla, CA.
The SDVG/TCA Quick Pitch competition offers a venue for leading startups to gain exposure to the most influential sources of private venture capital and other key strategic partners throughout Southern California. Selection to one of the coveted Top 10 pitch slots is considered a significant recognition of entrepreneurial achievement, as well as a key indicator of startups' future success.
Evasyst, a Cove Fund portfolio company, is developing EVA, an all-in-one social gaming discovery app where you can seamlessly play, spectate, & new groups of friends from around the world. EVA makes it easy for you to always stay up to date with what's new and current happening around you, right now.
Lynx Biosciences (LynxBio), another Cove Fund portfolio company, is commercializing a microfluidic platform technology to rapidly identify effective treatment options for cancer patients by characterizing individual patients' cancer behavior and disease evolution. LynxBio's product, MicroC3T, uses a standard-of-care biopsy to create a living model of a patient's cancer, including the patient's own microenvironment.
For more information, please contact Julie Cranston at Cove Fund II, LLC (firstname.lastname@example.org), Justin Weissberg at Evasyst (email@example.com), or Chorom Pak at Lynx Biosciences (firstname.lastname@example.org).